Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
immatics
Biotech
As investors pivot from cell therapy, Immatics keeps the faith
The biotech is planning for a potential commercial launch in the third quarter of 2027, a market debut Immatics intends to fund on its own.
Gabrielle Masson
Jun 6, 2025 3:50am
ASCO: Immatics cell therapy sees 56% ORR in advanced melanoma
May 31, 2025 8:00am
Bristol Myers culls cell therapy deals with 2 biotechs
Dec 16, 2024 11:19am
Immatics leaps into phase 3 on strength of early-stage PFS data
Oct 10, 2024 8:49am
ESMO: Bristol Myers axes Immatics' bispecific after $150M bet
Sep 16, 2024 6:59am
With $1.7B Immatics deal, Moderna bets again on cancer vaccines
Sep 11, 2023 8:12am
